Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Mar;73(6):803–804. doi: 10.1038/bjc.1996.140

Tallimustine in advanced previously untreated colorectal cancer, a phase II study.

C J Punt 1, Y Humblet 1, E Roca 1, L Y Dirix 1, R Wainstein 1, A Polli 1, I Corradino 1
PMCID: PMC2074363  PMID: 8611384

Abstract

Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown significant anti-tumour effects in animal models. We performed a phase II study in previously untreated patients with advanced colorectal cancer, using a schedule of i.v. bolus infusions of 900 microgram m-2 once every 4 weeks. Seventeen patients were enrolled, and no responses were documented in 14 evaluable patients. Toxicity mainly consisted a highly selective neutropenia, which warrants further investigation of this agent in combination with myeloid growth factors.

Full text

PDF
803

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arcamone F. M., Animati F., Barbieri B., Configliacchi E., D'Alessio R., Geroni C., Giuliani F. C., Lazzari E., Menozzi M., Mongelli N. Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. J Med Chem. 1989 Apr;32(4):774–778. doi: 10.1021/jm00124a008. [DOI] [PubMed] [Google Scholar]
  2. Broggini M., Coley H. M., Mongelli N., Pesenti E., Wyatt M. D., Hartley J. A., D'Incalci M. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res. 1995 Jan 11;23(1):81–87. doi: 10.1093/nar/23.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Broggini M., Erba E., Ponti M., Ballinari D., Geroni C., Spreafico F., D'Incalci M. Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res. 1991 Jan 1;51(1):199–204. [PubMed] [Google Scholar]
  4. Capolongo L., Melegaro G., Broggini M., Mongelli N., Grandi M. Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517). Br J Cancer. 1993 Nov;68(5):916–919. doi: 10.1038/bjc.1993.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coley H. M., Mongelli N., D'Incalci M. The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents. Biochem Pharmacol. 1993 Feb 9;45(3):619–626. doi: 10.1016/0006-2952(93)90135-j. [DOI] [PubMed] [Google Scholar]
  6. Geroni C., Pesenti E., Tagliabue G., Ballinari D., Mongelli N., Broggini M., Erba E., D'Incalci M., Spreafico F., Grandi M. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies. Int J Cancer. 1993 Jan 21;53(2):308–314. doi: 10.1002/ijc.2910530223. [DOI] [PubMed] [Google Scholar]
  7. Montecucco A., Fontana M., Focher F., Lestingi M., Spadari S., Ciarrocchi G. Specific inhibition of human DNA ligase adenylation by a distamycin derivative possessing antitumor activity. Nucleic Acids Res. 1991 Mar 11;19(5):1067–1072. doi: 10.1093/nar/19.5.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pezzoni G., Grandi M., Biasoli G., Capolongo L., Ballinari D., Giuliani F. C., Barbieri B., Pastori A., Pesenti E., Mongelli N. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A. Br J Cancer. 1991 Dec;64(6):1047–1050. doi: 10.1038/bjc.1991.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Riganti F., Sironi M., Kankova M., D'Incalci M., Spreafico F., Mantovani A., Vecchi A. The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action. Int J Immunopharmacol. 1992 Feb;14(2):239–251. doi: 10.1016/0192-0561(92)90036-k. [DOI] [PubMed] [Google Scholar]
  10. Sessa C., Pagani O., Zurlo M. G., de Jong J., Hofmann C., Lassus M., Marrari P., Strolin Benedetti M., Cavalli F. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol. 1994 Dec;5(10):901–907. doi: 10.1093/oxfordjournals.annonc.a058728. [DOI] [PubMed] [Google Scholar]
  11. Volpe D. A., Du D. L., Zurlo M. G., Mongelli N., Murphy M. J. Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Invest New Drugs. 1992 Nov;10(4):255–261. doi: 10.1007/BF00944178. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES